

# Dupilumab for treating severe chronic rhinosinusitis with nasal polyps

Information for the public

Published: 18 February 2026

[www.nice.org.uk](http://www.nice.org.uk)

Dupilumab (Dupixent) is available on the NHS. It is a possible treatment for severe chronic rhinosinusitis with nasal polyps in adults if:

- it is used alongside an intranasal corticosteroid, and
- the condition is not controlled well enough by systemic corticosteroids or sinus surgery, and
- they have had at least 1 sinus surgery, and
- they have a SNOT-22 score of at least 50.

Systemic corticosteroids work throughout the whole body. They can include injections, infusions or medicines taken by mouth.

The SNOT-22 (22-item sinonasal outcomes test) is a questionnaire that measures how nasal and sinus symptoms affect everyday life.

If you are not eligible for dupilumab but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on sinusitis](#) and [NHS webpage on nasal polyps](#) may be good places to find out more.

These organisations can give you advice and support:

- [SmellTaste](#), email: [info@smelltaste.org.uk](mailto:info@smelltaste.org.uk)
- [Sinus UK](#), email: [hello@sinusuk.org](mailto:hello@sinusuk.org)

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9280-5